Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1984 Feb;43(2):631–636. doi: 10.1128/iai.43.2.631-636.1984

Biological behavior of tumors and associated retroviremia in cats inoculated with Snyder-Theilen fibrosarcoma virus and the phenomenon of tumor recurrence after primary regression.

N C Pedersen, L Johnson, G H Theilen
PMCID: PMC264346  PMID: 6319286

Abstract

The fate of tumors and associated retroviremia was studied in 111 cats infected with the Snyder-Theilen strain of feline sarcoma virus (FeSV). Tumors appeared at the site of inoculation within 7 to 10 days. A retroviremia, due mainly to the associated feline leukemia virus helper virus (FeLV-helper), developed at the same time as tumors. Of the cats, 44 developed progressively growing tumors and therefore had to be killed, and 67 developed tumors that regressed. There was a strong correlation between the persistence of the accompanying retroviremia and the growth of the tumors. The 44 cats with progressively growing fibrosarcomas remained retroviremic until death. Conversely, 53 of the 67 cats with solitary, regressing tumors were only transiently retroviremic. Tumor regression in these cats paralleled the disappearance of retrovirus from the blood. The fate of tumors and retroviremia was not always the same, however. Twelve cats remained persistently retroviremic after all signs of gross tumors disappeared. Two other kittens became nonviremic within 20 days after inoculation, yet tumors continued to grow and even metastasize for another 3 to 5 weeks before regressing. Fibrosarcomas recurred 3 weeks to 8 months later in 8 of 12 persistently retroviremic cats with regressed tumors. Although the blood and bone marrow from these cats contained predominantly FeLV-helper, tumor cells yielded both FeSV and FeLV-helper. Of 53 animals, 3 developed recurrent fibrosarcomas 5 weeks to 8 months after all signs of tumors and retroviremia had disappeared. Cells cultured from these tumors appeared initially like normal fibroblasts and were virus nonproducers. After one to three passages in culture, however, cells became malignantly transformed and replicated both FeSV and FeLV-helper. Cultures of the bone marrow from these and other nonviremic cats with regressed tumors yielded only FeLV-helper.

Full text

PDF
631

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aldrich C. D., Pedersen N. C. Persistent viremia after regression of primary virus-induced feline fibrosarcomas. Am J Vet Res. 1974 Nov;35(11):1383–1387. [PubMed] [Google Scholar]
  2. Essex M., Klein G., Snyder S. P., Harrold J. B. Correlation between humoral antibody and regression of tumours induced by feline sarcoma virus. Nature. 1971 Sep 17;233(5316):195–196. doi: 10.1038/233195a0. [DOI] [PubMed] [Google Scholar]
  3. Fischinger P. J., Blevins C. S., Nomura S. Simple, quantitative assay for both xenotropic murine leukemia and ecotropic feline leukemia viruses. J Virol. 1974 Jul;14(1):177–179. doi: 10.1128/jvi.14.1.177-179.1974. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Gardner M. B., Arnstein P., Johnson E., Rongey R. W., Charman H. P., Huebner R. J. Feline sarcoma virus tumor induction in cats and dogs. J Am Vet Med Assoc. 1971 Mar 15;158(6 Suppl):1046+–1046+. [PubMed] [Google Scholar]
  5. Kurth R., Fenyö E. M., Klein E., Essex M. Cell-surface antigens induced by RNA tumour viruses. Nature. 1979 May 17;279(5710):197–201. doi: 10.1038/279197a0. [DOI] [PubMed] [Google Scholar]
  6. Levy J. P., Leclerc J. C. The murine sarcoma virus-induced tumor: exception or general model in tumor immunology? Adv Cancer Res. 1977;24:1–66. doi: 10.1016/s0065-230x(08)61012-x. [DOI] [PubMed] [Google Scholar]
  7. Lutz H., Pedersen N. C., Durbin R., Theilen G. H. Monoclonal antibodies to three epitopic regions of feline leukemia virus p27 and their use in enzyme-linked immunosorbent assay of p27. J Immunol Methods. 1983 Jan 28;56(2):209–220. doi: 10.1016/0022-1759(83)90413-1. [DOI] [PubMed] [Google Scholar]
  8. Mathes L. E., Olsen R. G., Hebebrand L. C., Hoover E. A., Schaller J. P., Adams P. W., Nichols W. S. Immunosuppressive properties of a virion polypeptide, a 15,000-dalton protein, from feline leukemia virus. Cancer Res. 1979 Mar;39(3):950–955. [PubMed] [Google Scholar]
  9. Rojko J. L., Hoover E. A., Quackenbush S. L., Olsen R. G. Reactivation of latent feline leukaemia virus infection. Nature. 1982 Jul 22;298(5872):385–388. doi: 10.1038/298385a0. [DOI] [PubMed] [Google Scholar]
  10. Sarma P. S., Log T., Theilen G. H. ST feline sarcoma virus. Biological characteristics and in vitro propagation. Proc Soc Exp Biol Med. 1971 Sep;137(4):1444–1448. doi: 10.3181/00379727-137-35807. [DOI] [PubMed] [Google Scholar]
  11. Schaller J. P., Essex M., Yohn D. S., Olsen R. G. Feline oncornavirus-associated cell membrane antigen. V. Humoral immune response to virus and cell membrane antigens in cats inoculated with Gardner-Arnstein feline sarcoma virus. J Natl Cancer Inst. 1975 Dec;55(6):1373–1378. doi: 10.1093/jnci/55.6.1373. [DOI] [PubMed] [Google Scholar]
  12. Snyder S. P., Dungworth D. L. Pathogenesis of feline viral fibrosarcomas: dose and age effects. J Natl Cancer Inst. 1973 Sep;51(3):793–798. doi: 10.1093/jnci/51.3.793. [DOI] [PubMed] [Google Scholar]
  13. Snyder S. P., Theilen G. H. Transmissible feline fibrosarcoma. Nature. 1969 Mar 15;221(5185):1074–1075. doi: 10.1038/2211074a0. [DOI] [PubMed] [Google Scholar]
  14. Wolfe L. G., Smith R. D., Hoekstra J., Marczynska B., Smith R. K., McDonald R., Northrop R. L., Deinhardt F. Oncogenicity of feline fibrosarcoma viruses in marmoset monkeys: pathologic, virologic, and immunologic findings. J Natl Cancer Inst. 1972 Aug;49(2):519–539. [PubMed] [Google Scholar]
  15. de Noronha F., Grant C. K., Lutz H., Keyes A., Rowston W. Circulating levels of feline leukemia and sarcoma viruses and fibrosarcoma regression in persistently viremic cats. Cancer Res. 1983 Apr;43(4):1663–1668. [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES